Finch Therapeutics Group
VerifiedA clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
Launch date
Employees
Market cap
$3.7m
Net debt
($5.0m)
Enterprise valuation
$9m (Public information from May 2024)
Share price
$2.03 FNCH
Somerville Massachusetts (HQ)
Deals in current and previous year:
No columns specified